ReviewJournal of proteome research2008
Breast tumor microenvironment: proteomics highlights the treatments targeting secretome.
Review in Journal of proteome research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 64 citations in OpenAlex.
- SERPINA3 as a Secreted-Protein Biomarker Associated with Poor Prognosis and T-Cell Dysfunction in Non-small Cell Lung Cancer.Tuberculosis and respiratory diseases · 2026Article
- Tumor secretome shapes the immune landscape during cancer progression.Journal of experimental & clinical cancer research : CR · 2025Review
- Forces at play: exploring factors affecting the cancer metastasis.Frontiers in immunology · 2024Review
- Study on the Relationship Between Differentially Expressed Proteins in Breast Cancer and Lymph Node Metastasis.Advances in therapy · 2023Article
- Passing the post: roles of posttranslational modifications in the form and function of extracellular matrix.American journal of physiology. Cell physiology · 2023Review
- The Variety of 3D Breast Cancer Models for the Study of Tumor Physiology and Drug Screening.International journal of molecular sciences · 2023Review
- Secretome profiling ofFrontiers in oncology · 2023Article
- Review
- A robust strategy for proteomic identification of biomarkers of invasive phenotype complexed with extracellular heat shock proteins.Cell stress & chaperones · 2019Article
- ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs.Scientific reports · 2019Article
- Cellular Interactions in the Tumor Microenvironment: The Role of Secretome.Journal of Cancer · 2019Review
- Novel function of E26 transformation-specific domain-containing protein ELK3 in lymphatic endothelial cells.Oncology letters · 2018Article
- Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers.Oncotarget · 2017Article
- Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.Breast cancer research and treatment · 2015Observational
- Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes.Scientific reports · 2015Article
- YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment.Oncotarget · 2015Article
- Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment.Expert reviews in molecular medicine · 2015Review
- Secretomes are a potential source of molecular targets for cancer therapies and indicate that APOE is a candidate biomarker for lung adenocarcinoma metastasis.Molecular biology reports · 2014Article
- Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Tumor secreted substances (secretome), including extracellular matrix (ECM) components, act as mediators of tumor-host communication in the breast tumor microenvironment. Proteomic analysis has emphasized the value of the secretome as a source of prospective markers and drug targets for the treatment of breast cancers. Utilizing bioinformatics, our recent studies revealed global changes in protein expression after the activation of ECM-mediated signaling in breast cancer cells. A newly designed technique integrating a capillary ultrafiltration (CUF) probe with mass spectrometry was demonstrated to dynamically sample and identify in vivo and pure secretome from the tumor microenvironment. Such in vivo profiling of breast cancer secretomes may facilitate the development of novel drugs specifically targeting secretome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.